

41



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 11 2004

In re PATENT APPLICATION OF:

Applicant: **Oliver Yoa-Pu HU et al.**

Serial No. **10/080,043**

Filing Date: **February 22, 2002**

For: **CYTOCHROME P450 3A
INHIBITORS AND
ENHANCERS**

) Group Art Unit: **1614**

) Examiner: **Phyllis G. Spivack**

) Customer No.

) ***26694***

) **26694**

) PATENT TRADEMARK OFFICE

Atty. Docket No. **39297-174169**

March 10, 2004

Commission for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Non-Fee Amendment

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Office Action dated February 10, 2004, Applicant hereby responds to the Restriction Requirement by electing Group I, Claims 1-15, 24, 25, drawn to CYP3A inhibitors alone and in combination with a drug, and methods of use thereof, classified in various subclasses of class 514, depending on the compounds contemplated, with traverse. Also, under 35 U.S.C. 121 to elect single disclosed species, applicant elects "swertiamarin". Applicants respectfully request that the Examiner consider to withdraw the Restriction Order.

It is respectfully submitted that this application is now in condition for examination on the merits, and early action and allowance thereof is accordingly requested.

BEST AVAILABLE COPY

Respectfully submitted,

A handwritten signature in cursive script that reads "Fei-Fei Chao".

Fei-Fei Chao, Ph.D.
Reg. No. 43,538

Date: March 10, 2004

Fei-Fei Chao, Ph.D.
Venable LLP
575 7th Street, N.W.
Washington, D.C. 20004

(202)-344-8011

DCDocs2/530025